Complement C5 Inhibitors & C5 Receptor Antagonists Pipeline Market Research Report 2026: Soliris and Ultomiris from AstraZeneca and Piasky Have Set the Stage for Next ...

Opportunities in the C5 inhibitors market include developing next-gen biosimilars and biosuperiors to improve administration frequency and expand treatment indications for diseases like aHUS, SCD, MG, ...
Seeking Alpha

Dianthus: Improved Autoimmune Disorder Targeting With Classical Pathway Inhibition

Dianthus Therapeutics, Inc. (DNTH) is advancing its potential best-in-class complement inhibitor drug DNTH103 for a wide variety of autoimmune disorders. In particular, it is looking at advancing the ...
The American Journal of Managed Care

Positioning Emerging Targeted Therapies in the Evolving IgA Nephropathy Treatment Paradigm

This episode, titled Positioning Emerging Targeted Therapies in the Evolving IgA Nephropathy Treatment Paradigm, features ...
Renal & Urology News

Thrombospondin-1 Limits Complement-Mediated Injury in AAV

TSP-1 reduced C3 and C5 cleavage and formation of the membrane attack complex, attenuating complement-mediated injury in AAV models. Complement activation is a relevant driver in the pathomechanisms ...
Business Wire

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it has dosed the first subjects in a Phase 1/2a clinical trial (NCT06209177) of ARO-CFB, the ...
Medscape

C-reactive Protein at the Interface Between Innate Immunity and Inflammation

Expert Rev Clin Immunol. 2008;4(3):379-390. Since there are no genetic deficiencies of CRP in man, animal models have been used to study the role of CRP in inflammatory disease. Two methods have been ...